HC Wainwright Reiterates “Buy” Rating for Replimune Group (NASDAQ:REPL)

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research note issued to investors on Tuesday, TipRanks reports. HC Wainwright currently has a $60.00 target price on the stock.

A number of other equities analysts have also issued reports on REPL. Zacks Investment Research lowered Replimune Group from a hold rating to a sell rating in a research note on Thursday, January 6th. BTIG Research began coverage on Replimune Group in a research note on Friday, October 15th. They set a buy rating and a $60.00 price target for the company. Finally, Piper Sandler began coverage on Replimune Group in a research note on Friday, November 19th. They set an overweight rating and a $52.00 price target for the company. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, Replimune Group currently has an average rating of Buy and a consensus target price of $55.25.

Shares of NASDAQ REPL opened at $23.87 on Tuesday. The stock has a fifty day moving average price of $28.97 and a two-hundred day moving average price of $31.37. The company has a quick ratio of 26.71, a current ratio of 26.71 and a debt-to-equity ratio of 0.05. Replimune Group has a 1 year low of $22.13 and a 1 year high of $46.64.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Thursday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). On average, research analysts expect that Replimune Group will post -2.27 earnings per share for the current year.

In other news, COO Colin Love sold 12,711 shares of the firm’s stock in a transaction on Monday, October 18th. The stock was sold at an average price of $29.58, for a total value of $375,991.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fund Iv L.P. Omega sold 25,225 shares of the firm’s stock in a transaction on Thursday, November 4th. The stock was sold at an average price of $33.58, for a total value of $847,055.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,384 shares of company stock valued at $2,594,207. Corporate insiders own 40.30% of the company’s stock.

Several institutional investors have recently modified their holdings of REPL. FORA Capital LLC acquired a new stake in shares of Replimune Group in the second quarter worth $40,000. Dark Forest Capital Management LP acquired a new stake in shares of Replimune Group in the second quarter worth $86,000. Point72 Hong Kong Ltd acquired a new stake in shares of Replimune Group in the third quarter worth $108,000. Royal Bank of Canada raised its holdings in shares of Replimune Group by 15.8% during the third quarter. Royal Bank of Canada now owns 4,804 shares of the company’s stock worth $143,000 after acquiring an additional 657 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Replimune Group by 455.1% during the third quarter. BNP Paribas Arbitrage SA now owns 5,601 shares of the company’s stock worth $166,000 after acquiring an additional 4,592 shares in the last quarter. 74.08% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.

Further Reading: What does a bar chart display?

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.